{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:13:48Z","timestamp":1790489628736,"version":"4.1.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T00:00:00Z","timestamp":1504569600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Astellas Pharma Inc"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s40273-017-0540-2","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T17:40:47Z","timestamp":1504633247000},"page":"1123-1140","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["A Systematic Literature Review of Economic Evaluations of Antibiotic Treatments for Clostridium difficile Infection"],"prefix":"10.1007","volume":"35","author":[{"given":"Hannah E.","family":"Burton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen A.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Watt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"issue":"8","key":"540_CR1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.medmal.2014.04.002","volume":"44","author":"A Monnier Le","year":"2014","unstructured":"Le Monnier A, Zahar JR, Barbut F. Update on Clostridium difficile infections. Medecine et maladies infectieuses. 2014;44(8):354\u201365.","journal-title":"Medecine et maladies infectieuses."},{"key":"540_CR2","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.micpath.2016.05.018","volume":"97","author":"C Rodriguez","year":"2016","unstructured":"Rodriguez C, Van Broeck J, Taminiau B, Delmee M, Daube G. Clostridium difficile infection: early history, diagnosis and molecular strain typing methods. Microb Pathog. 2016;97:59\u201378.","journal-title":"Microb Pathog"},{"key":"540_CR3","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.anaerobe.2015.04.012","volume":"34","author":"K Shields","year":"2015","unstructured":"Shields K, Araujo-Castillo RV, Theethira TG, Alonso CD, Kelly CP. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe. 2015;34:59\u201373.","journal-title":"Anaerobe"},{"issue":"1","key":"540_CR4","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.idc.2014.11.003","volume":"29","author":"JH Kwon","year":"2015","unstructured":"Kwon JH, Olsen MA, Dubberke ER. The morbidity, mortality, and costs associated with Clostridium difficile infection. Infect Dis Clin N Am. 2015;29(1):123\u201334.","journal-title":"Infect Dis Clin N Am"},{"issue":"1","key":"540_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jhin.2012.02.004","volume":"81","author":"PN Wiegand","year":"2012","unstructured":"Wiegand PN, Nathwani D, Wilcox MH, Stephens J, Shelbaya A, Haider S. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect. 2012;81(1):1\u201314.","journal-title":"J Hosp Infect."},{"issue":"Suppl 6","key":"540_CR6","first-page":"21","volume":"18","author":"CP Kelly","year":"2012","unstructured":"Kelly CP. Can we identify patients at high risk of recurrent Clostridium difficile infection? Clin Microbiol Infect. 2012;18(Suppl 6):21\u20137.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"issue":"2","key":"540_CR7","first-page":"147","volume":"29","author":"A Ofosu","year":"2016","unstructured":"Ofosu A. Clostridium difficile infection: a review of current and emerging therapies. Ann Gastroenterol Q Publ Hell Soc Gastroenterol. 2016;29(2):147\u201354.","journal-title":"Ann Gastroenterol Q Publ Hell Soc Gastroenterol."},{"issue":"1","key":"540_CR8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijantimicag.2012.01.004","volume":"40","author":"KZ Vardakas","year":"2012","unstructured":"Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G, Falagas ME. Treatment failure and recurrence of Clostridium difficile infection following treatment with vancomycin or metronidazole: a systematic review of the evidence. Int J Antimicrob Agents. 2012;40(1):1\u20138.","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"540_CR9","first-page":"411","volume":"4","author":"Y Vincent","year":"2015","unstructured":"Vincent Y, Manji A, Gregory-Miller K, Lee C. A review of management of Clostridium difficile infection: primary and recurrence. Antibiotics (Basel, Switzerland). 2015;4(4):411\u201323.","journal-title":"Antibiotics (Basel, Switzerland)."},{"issue":"6","key":"540_CR10","doi-asserted-by":"crossref","first-page":"361","DOI":"10.4212\/cjhp.v66i6.1301","volume":"66","author":"C Leong","year":"2013","unstructured":"Leong C, Zelenitsky S. Treatment strategies for recurrent Clostridium difficile infection. Can J Hosp Pharm. 2013;66(6):361\u20138.","journal-title":"Can J Hosp Pharm."},{"key":"540_CR11","doi-asserted-by":"crossref","unstructured":"van Nood E, Speelman P, Kuijper EJ, Keller JJ. Struggling with recurrent Clostridium difficile infections: is donor faeces the solution? Euro surveillance: bulletin Europeen sur les maladies transmissibles (European communicable disease bulletin). 2009;14(34). pii: 19316.","DOI":"10.2807\/ese.14.34.19316-en"},{"issue":"Suppl 6","key":"540_CR12","first-page":"2","volume":"18","author":"F Fitzpatrick","year":"2012","unstructured":"Fitzpatrick F, Barbut F. Breaking the cycle of recurrent Clostridium difficile infections. Clin Microbiol Infect. 2012;18(Suppl 6):2\u20134.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"issue":"4","key":"540_CR13","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.jhin.2009.10.016","volume":"74","author":"SS Ghantoji","year":"2010","unstructured":"Ghantoji SS, Sail K, Lairson DR, DuPont HL, Garey KW. Economic healthcare costs of Clostridium difficile infection: a systematic review. J Hosp Infect. 2010;74(4):309\u201318.","journal-title":"J Hosp Infect."},{"issue":"2","key":"540_CR14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1046\/j.1365-2710.2000.00266.x","volume":"25","author":"FA Al-Eidan","year":"2000","unstructured":"Al-Eidan FA, McElnay JC, Scott MG, Kearney MP. Clostridium difficile-associated diarrhoea in hospitalised patients. J Clin Pharm Ther. 2000;25(2):101\u20139.","journal-title":"J Clin Pharm Ther"},{"issue":"Suppl 6","key":"540_CR15","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/1469-0691.12064","volume":"18","author":"E Bouza","year":"2012","unstructured":"Bouza E. Consequences of Clostridium difficile infection: understanding the healthcare burden. Clin Microbiol Infect. 2012;18(Suppl 6):5\u201312.","journal-title":"Clin Microbiol Infect."},{"issue":"Suppl 2","key":"540_CR16","doi-asserted-by":"crossref","first-page":"S162","DOI":"10.1093\/cid\/cis453","volume":"55","author":"F Babakhani","year":"2012","unstructured":"Babakhani F, Bouillaut L, Gomez A, Sears P, Nguyen L, Sonenshein AL. Fidaxomicin inhibits spore production in Clostridium difficile. Clin Infect Dis. 2012;55(Suppl 2):S162\u20139.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"issue":"Pt 8","key":"540_CR17","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","volume":"60","author":"F Babakhani","year":"2011","unstructured":"Babakhani F, Gomez A, Robert N, Sears P. Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile. J Med Microbiol. 2011;60(Pt 8):1213\u20137.","journal-title":"J Med Microbiol"},{"issue":"Pt 11","key":"540_CR18","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1099\/mic.0.042010-0","volume":"156","author":"GW Tannock","year":"2010","unstructured":"Tannock GW, Munro K, Taylor C, Lawley B, Young W, Byrne B, et al. A new macrocyclic antibiotic, fidaxomicin (OPT-80), causes less alteration to the bowel microbiota of Clostridium difficile-infected patients than does vancomycin. Microbiology (Reading, England). 2010;156(Pt 11):3354\u20139.","journal-title":"Microbiology (Reading, England)."},{"issue":"2","key":"540_CR19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1017\/ice.2015.270","volume":"37","author":"ST Housman","year":"2016","unstructured":"Housman ST, Thabit AK, Kuti JL, Quintiliani R, Nicolau DP. Assessment of Clostridium difficile burden in patients over time with first episode infection following fidaxomicin or vancomycin. Infect Control Hosp Epidemiol. 2016;37(2):215\u20138.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"8","key":"540_CR20","doi-asserted-by":"crossref","first-page":"e0161200","DOI":"10.1371\/journal.pone.0161200","volume":"11","author":"CH Chilton","year":"2016","unstructured":"Chilton CH, Crowther GS, Ashwin H, Longshaw CM, Wilcox MH. Association of fidaxomicin with C. difficile spores: effects of persistence on subsequent spore recovery, outgrowth and toxin production. PLoS One. 2016;11(8):e0161200.","journal-title":"PLoS One"},{"issue":"4","key":"540_CR21","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1473-3099(11)70374-7","volume":"12","author":"OA Cornely","year":"2012","unstructured":"Cornely OA, Crook DW, Esposito R, Poirier A, Somero MS, Weiss K, et al. Fidaxomicin versus vancomycin for infection with Clostridium difficile in Europe, Canada, and the USA: a double-blind, non-inferiority, randomised controlled trial. Lancet Infect Dis. 2012;12(4):281\u20139.","journal-title":"Lancet Infect Dis."},{"issue":"5","key":"540_CR22","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, Weiss K, Lentnek A, Golan Y, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med. 2011;364(5):422\u201331.","journal-title":"N Engl J Med"},{"issue":"11","key":"540_CR23","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1093\/jac\/dku261","volume":"69","author":"OA Cornely","year":"2014","unstructured":"Cornely OA, Nathwani D, Ivanescu C, Odufowora-Sita O, Retsa P, Odeyemi IA. Clinical efficacy of fidaxomicin compared with vancomycin and metronidazole in Clostridium difficile infections: a meta-analysis and indirect treatment comparison. J Antimicrob Chemother. 2014;69(11):2892\u2013900.","journal-title":"J Antimicrob Chemother."},{"issue":"2","key":"540_CR24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/2040622313511285","volume":"5","author":"K Mullane","year":"2014","unstructured":"Mullane K. Fidaxomicin in Clostridium difficile infection: latest evidence and clinical guidance. Ther Adv Chronic Dis. 2014;5(2):69\u201384.","journal-title":"Ther Adv Chronic Dis."},{"key":"540_CR25","unstructured":"Watt M, McCrea C, Posnett J, Berling M, Odeyemi IA. Cost-effectiveness of fidaxomicin for the treatment of Clostridium difficile infection in England. Abstract presented at Federation of Infection Societies Annual Conference, Birmingham, UK, 11\u201313 Nov 2013."},{"issue":"11","key":"540_CR26","doi-asserted-by":"crossref","first-page":"2901","DOI":"10.1093\/jac\/dku257","volume":"69","author":"D Nathwani","year":"2014","unstructured":"Nathwani D, Cornely OA, Van Engen AK, Odufowora-Sita O, Retsa P, Odeyemi IA. Cost-effectiveness analysis of fidaxomicin versus vancomycin in Clostridium difficile infection. J Antimicrob Chemother. 2014;69(11):2901\u201312.","journal-title":"J Antimicrob Chemother."},{"key":"540_CR27","doi-asserted-by":"crossref","unstructured":"Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany. Infection. 2016;44(5):599\u2013606.","DOI":"10.1007\/s15010-016-0894-y"},{"issue":"2","key":"540_CR28","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jval.2012.11.004","volume":"16","author":"PM Stranges","year":"2013","unstructured":"Stranges PM, Hutton DW, Collins CD. Cost-effectiveness analysis evaluating fidaxomicin versus oral vancomycin for the treatment of Clostridium difficile infection in the United States. Value Health. 2013;16(2):297\u2013304.","journal-title":"Value Health."},{"issue":"2","key":"540_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1155\/2014\/793532","volume":"25","author":"M Wagner","year":"2014","unstructured":"Wagner M, Lavoie L, Goetghebeur M. Clinical and economic consequences of vancomycin and fidaxomicin for the treatment of Clostridium difficile infection in Canada. Can J Infect Dis Med Microbiol. 2014;25(2):87\u201394.","journal-title":"Can J Infect Dis Med Microbiol."},{"key":"540_CR30","unstructured":"Centre for Reviews and Dissemination. Systematic Reviews: CRD\u2019s guidance for undertaking reviews in health care 2009. https:\/\/www.york.ac.uk\/media\/crd\/Systematic_Reviews.pdf . Accessed Aug 2017."},{"key":"540_CR31","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions. 2011. Version 5.1.0: http:\/\/handbook.cochrane.org . Accessed Aug 2017."},{"issue":"Suppl 2","key":"540_CR32","first-page":"1","volume":"20","author":"SB Debast","year":"2014","unstructured":"Debast SB, Bauer MP, Kuijper EJ. European society of clinical microbiology and infectious diseases: update of the treatment guidance document for Clostridium difficile infection. Clin Microbiol Infect. 2014;20(Suppl 2):1\u201326.","journal-title":"Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis."},{"issue":"4","key":"540_CR33","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1038\/ajg.2013.4","volume":"108","author":"CM Surawicz","year":"2013","unstructured":"Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108(4):478\u201398.","journal-title":"Am J Gastroenterol."},{"issue":"5","key":"540_CR34","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","volume":"31","author":"SH Cohen","year":"2010","unstructured":"Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431\u201355.","journal-title":"Infect Control Hosp Epidemiol"},{"issue":"7052","key":"540_CR35","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1136\/bmj.313.7052.275","volume":"313","author":"MF Drummond","year":"1996","unstructured":"Drummond MF, Jefferson TO. Guidelines for authors and peer reviewers of economic submissions to the BMJ. The BMJ economic evaluation working party. BMJ. 1996;313(7052):275\u201383.","journal-title":"BMJ"},{"issue":"4","key":"540_CR36","doi-asserted-by":"crossref","first-page":"A243","DOI":"10.1016\/j.jval.2012.03.1311","volume":"15","author":"M Alowayesh","year":"2012","unstructured":"Alowayesh M, Holdford D, Harpe SE. PIN35 decision analysis model evaluating the cost-effectiveness of fidaxomicin and vancomycin in the treatment of Clostridium difficile infection (CDI) from a hospital perspective. Value Health. 2012;15(4):A243.","journal-title":"Value Health"},{"issue":"4","key":"540_CR37","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1093\/cid\/cit346","volume":"57","author":"SM Bartsch","year":"2013","unstructured":"Bartsch SM, Umscheid CA, Fishman N, Lee BY. Is fidaxomicin worth the cost? An economic analysis. Clin Infect Dis. 2013;57(4):555\u201361.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"540_CR38","doi-asserted-by":"crossref","unstructured":"Biltaji E, Varier R, Smith K, Roberts M, Lafleur J, Nelson R. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Value Health. 2014;17(3):A38.","DOI":"10.1016\/j.jval.2014.03.231"},{"key":"540_CR39","unstructured":"Bott Q, Rice L, Oh J, Sinha V, Boyer N. Cost-effectiveness of fidaxomicin for the treatment of severe Clostridium difficile infection in hospitalized patients in North America. Pharmacotherapy. 2012;32(10):e292."},{"key":"540_CR40","doi-asserted-by":"crossref","unstructured":"Brodszky V, Strbak B, Baji P, Pentek M, Gulacsi L. Cost-effectiveness of fidaxomicin therapy for Clostridium difficile infection in Hungary. Value Health. 2014;17(7):A675.","DOI":"10.1016\/j.jval.2014.08.2505"},{"key":"540_CR41","doi-asserted-by":"crossref","first-page":"A674","DOI":"10.1016\/j.jval.2014.08.2501","volume":"17","author":"J Cobo Reinoso","year":"2014","unstructured":"Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Llet\u00ed M, Toledo A, Anguita P, et al. Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infections (CDI) also known as Clostridium difficile-associated diarrhoea (CDAD) in Spain. Value Health. 2014;17:A674.","journal-title":"Value Health."},{"issue":"11","key":"540_CR42","doi-asserted-by":"crossref","first-page":"7007","DOI":"10.1128\/AAC.00939-15","volume":"59","author":"JC Gallagher","year":"2015","unstructured":"Gallagher JC, Reilly JP, Navalkele B, Downham G, Haynes K, Trivedi M. Clinical and economic benefits of fidaxomicin compared to vancomycin for Clostridium difficile infection. Antimicrob Agents Chemother. 2015;59(11):7007\u201310.","journal-title":"Antimicrob Agents Chemother"},{"key":"540_CR43","unstructured":"Heimann SM, Cornely OA, Vehreschild MJGT, Vehreschild JJ, editors. Pharmacoeconomical decision-tree analysis of Clostridium difficile-associated diarrhea in patients with cancer treated with fidaxomicin or vancomycin. Abstract presented at ICAAC, Washington DC, USA, 5\u20139 Sept 2014."},{"key":"540_CR44","doi-asserted-by":"crossref","unstructured":"Karkow D, Schroeder M, Ince D, Ernst E, editors. Cost-effectiveness analysis of vancomycin versus metronidazole for management of initial episodes of Clostridium difficile infection in hospitalized patients. Abstract presented at\u00a0IDWeek, San Diego, USA, 7\u201311 Oct 2015.","DOI":"10.1093\/ofid\/ofv133.673"},{"key":"540_CR45","doi-asserted-by":"crossref","unstructured":"Konijeti G, Sauk J, Shime M, Ananthakrishnan A. Cost-effectiveness of competing strategies for recurrent Clostridium difficile infection. Am J Gastroenterol. 2013;108:S473.","DOI":"10.14309\/00000434-201310001-01579"},{"issue":"11","key":"540_CR46","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1093\/cid\/ciu128","volume":"58","author":"GG Konijeti","year":"2014","unstructured":"Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-effectiveness of competing strategies for management of recurrent Clostridium difficile infection: a decision analysis. Clin Infect Dis. 2014;58(11):1507\u201314.","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am."},{"key":"540_CR47","doi-asserted-by":"crossref","first-page":"A498","DOI":"10.1016\/j.jval.2013.08.1123","volume":"16","author":"M Lamotte","year":"2013","unstructured":"Lamotte M, Vellopoulou K, Richir K, Smets J, Grabe K, Coppens K. The cost-utility of fidaxomicin as compared to current standard treatment in the management of Clostridium difficile infections in Belgium. Value Health. 2013;16:A498.","journal-title":"Value Health."},{"issue":"2","key":"540_CR48","doi-asserted-by":"crossref","first-page":"e0149521","DOI":"10.1371\/journal.pone.0149521","volume":"11","author":"L Lapointe-Shaw","year":"2016","unstructured":"Lapointe-Shaw L, Tran KL, Coyte PC, Hancock-Howard RL, Powis J, Poutanen SM, et al. Cost-effectiveness analysis of six strategies to treat recurrent Clostridium difficile infection. PLoS One. 2016;11(2):e0149521.","journal-title":"PLoS One"},{"issue":"4","key":"540_CR49","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jval.2012.03.748","volume":"15","author":"N Madkour","year":"2012","unstructured":"Madkour N, Bounthavong M, Hsu D. A comparison of the cost-effectiveness of fidaxomicin, metronidazole, and vancomycin, in the treatment of Clostridium difficile-associated disease. Value Health. 2012;15(4):2.","journal-title":"Value Health."},{"key":"540_CR50","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.vhri.2014.02.005","volume":"4","author":"M Markovi\u0107","year":"2014","unstructured":"Markovi\u0107 M, Kostic M, Ilickovic I, Jankovic S. Cost-effectiveness comparison of fidaxomicin and vancomycin for treatment of Clostridium difficile infection: a Markov model based on data from a South West Balkan Country in Socioeconomic Transition. Value Health Reg Issues. 2014;4:8.","journal-title":"Value Health Reg Issues."},{"issue":"3","key":"540_CR51","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.jval.2014.03.1593","volume":"17","author":"S Massachi","year":"2014","unstructured":"Massachi S, Hay J. Cost-effectiveness of various Clostridium difficile infection (CDI) treatments in patients with recurrent infections. Value Health. 2014;17(3):2.","journal-title":"Value Health."},{"key":"540_CR52","doi-asserted-by":"crossref","first-page":"A270","DOI":"10.1016\/j.jval.2014.03.1574","volume":"17","author":"C McCrea","year":"2014","unstructured":"McCrea C, Perera S, Van Engen A, Watt M, Nazir J. Economic evaluation of fidaxomicin compared with vancomycin in the treatment of Clostridium difficile infection. Value Health. 2014;17:A270.","journal-title":"Value Health."},{"key":"540_CR53","volume-title":"Cost-effectiveness of fidaxomicin as first-line treatment for Clostridium difficile infection","author":"J Nesnas","year":"2014","unstructured":"Nesnas J, Whitney L, Ahmad A, Planche T. Cost-effectiveness of fidaxomicin as first-line treatment for Clostridium difficile infection. Abstract presented at ECCMID, Barcelona, Spain, 10\u201313 May 2014."},{"key":"540_CR54","first-page":"2","volume":"1","author":"S Patel","year":"2014","unstructured":"Patel SS, Grinspan A, Colombel J-F, Atreja A. Cost effectiveness analysis of fecal microbiota transplant and antibiotic treatment for recurrent Clostridium difficile infection. Gastroenterology. 2014;1:2.","journal-title":"Gastroenterology."},{"key":"540_CR55","unstructured":"Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K. Vancomycin or Metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. 2011. https:\/\/www.cadth.ca\/vancomycin-or-metronidazole-treatment-clostridium-difficile-infection-clinical-and-economic-analyses . Accessed Aug 2017."},{"key":"540_CR56","doi-asserted-by":"crossref","unstructured":"Petryszyn P, Well A. Cost-utility analysis of fidaxomicin compared to vancomycin in the management of severe Clostridium difficile infection in Poland. Value Health. 2014;17(7):A368.","DOI":"10.1016\/j.jval.2014.08.828"},{"key":"540_CR57","doi-asserted-by":"crossref","unstructured":"Planche T, Whitney L, Ahmad A, Nesnas J. Experience with fidaxomicin as first-line treatment for C. difficile infection (CDI): clinical outcomes and cost-effectiveness. Am J Gastroenterol. 2014;109:S678.","DOI":"10.14309\/00000434-201410002-02332"},{"issue":"11","key":"540_CR58","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1007\/s10096-015-2472-0","volume":"34","author":"C Rubio-Terr\u00e9s","year":"2015","unstructured":"Rubio-Terr\u00e9s C, Cobo Reinoso J, Grau Cerrato S, Mensa Pueyo J, Salavert Lleti M, Toledo A, et al. Economic assessment of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in special populations (patients with cancer, concomitant antibiotic treatment or renal impairment) in Spain. Eur J Clin Microbiol Infect Dis. 2015;34(11):2213\u201323.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"540_CR59","doi-asserted-by":"crossref","unstructured":"Singh P, Udeh B, Dalton J, Udeh C, Hata J. Cost-effectiveness of 6 treatments for primary Clostridium difficile infection in an ICU population. Crit Care Med. 2014;1:A1474.","DOI":"10.1097\/01.ccm.0000457970.56337.e3"},{"key":"540_CR60","unstructured":"Trevor N, Watt M, Tilleul P, Le Monnier A, Fau I, Ait-Yahia M, et al. Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infections in France. Abstract presented at Healthcare Infection Society Conference, Lyon, France, 16\u201318 Nov 2014."},{"key":"540_CR61","volume-title":"Cost-consequence analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection (CDI) in France","author":"N Trevor","year":"2015","unstructured":"Trevor N, Watt M, Tilleul P, Le Monnier A, Fau I, Ait-Yahia M, et al. Cost-consequence analysis on the use of fidaxomicin and vancomycin to treat Clostridium difficile infection (CDI) in France. Abstract presented at ECCMID, Copenhagen, Denmark, 25\u201328 Apr 2015."},{"key":"540_CR62","doi-asserted-by":"crossref","first-page":"192","DOI":"10.36469\/9903","volume":"2","author":"A Engen Van","year":"2015","unstructured":"Van Engen A, Casamayor M, Loftus F, Coen M, Garnham A, Watt M, et al. Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infection (C. difficile-associated diarrhoea) in Ireland. J Health Econ Outcomes Res. 2015;2:192\u20132026.","journal-title":"J Health Econ Outcomes Res."},{"key":"540_CR63","doi-asserted-by":"crossref","first-page":"A353","DOI":"10.1016\/j.jval.2013.08.179","volume":"16","author":"A Engen Van","year":"2013","unstructured":"Van Engen A, Casamayor M, Loftus F, Crimin E, Lacey L. Economic evaluation of fidaxomicin for the treatment of Clostridium difficile infections (CDI) also known as C. difficile-associated diarrhoea (CDAD) in Ireland. Value Health. 2013;16:A353.","journal-title":"Value Health."},{"issue":"7","key":"540_CR64","doi-asserted-by":"crossref","first-page":"A673","DOI":"10.1016\/j.jval.2014.08.2498","volume":"17","author":"A Engen Van","year":"2014","unstructured":"Van Engen A, Lie X, Noren T, Nordling S, Norgaard K. Cost-effectiveness of fidaxomicin for the treatment of Clostridium difficile infection (CDI) in Sweden. Value Health. 2014;17(7):A673\u20134.","journal-title":"Value Health."},{"issue":"12","key":"540_CR65","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1111\/1469-0691.12805","volume":"20","author":"RU Varier","year":"2014","unstructured":"Varier RU, Biltaji E, Smith KJ, Roberts MS, Jensen MK, LaFleur J, et al. Cost-effectiveness analysis of treatment strategies for initial Clostridium difficile infection. Clin Microbiol Infect. 2014;20(12):1343\u201351.","journal-title":"Clin Microbiol Infect."},{"key":"540_CR66","doi-asserted-by":"crossref","unstructured":"Watt M, McCrea C, Johal S, Posnett J, Nazir J. A cost-effectiveness and budget impact analysis of fidaxomicin for treating Clostridium difficile patients in Germany. Value Health. 2015;18(3):A233.","DOI":"10.1016\/j.jval.2015.03.1357"},{"issue":"6","key":"540_CR67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nrgastro.2011.59","volume":"8","author":"CM Surawicz","year":"2011","unstructured":"Surawicz CM, Alexander J. Treatment of refractory and recurrent Clostridium difficile infection. Nat Rev Gastroenterol Hepatol. 2011;8(6):330\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol."},{"issue":"49","key":"540_CR68","first-page":"iii","volume":"8","author":"MJ Sculpher","year":"2004","unstructured":"Sculpher MJ, Pang FS, Manca A, Drummond MF, Golder S, Urdahl H, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess (Winchester, England). 2004;8(49):iii\u2013iv (1\u2013192).","journal-title":"Health Technol Assess (Winchester, England)."},{"issue":"6","key":"540_CR69","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s15010-015-0810-x","volume":"43","author":"SM Heimann","year":"2015","unstructured":"Heimann SM, Vehreschild JJ, Cornely OA, Wisplinghoff H, Hallek M, Goldbrunner R, et al. Economic burden of Clostridium difficile associated diarrhoea: a cost-of-illness study from a German tertiary care hospital. Infection. 2015;43(6):707\u201314.","journal-title":"Infection"},{"issue":"8","key":"540_CR70","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1097\/MCG.0000000000000473","volume":"50","author":"KW Garey","year":"2016","unstructured":"Garey KW, Aitken SL, Gschwind L, Goddu S, Xie Y, Duff C, et al. Development and validation of a Clostridium difficile health-related quality-of-life questionnaire. J Clin Gastroenterol. 2016;50(8):631\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"2","key":"540_CR71","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s10096-015-2538-z","volume":"35","author":"SD Goldenberg","year":"2016","unstructured":"Goldenberg SD, Brown S, Edwards L, Gnanarajah D, Howard P, Jenkins D, et al. The impact of the introduction of fidaxomicin on the management of Clostridium difficile infection in seven NHS secondary care hospitals in England: a series of local service evaluations. Eur J Clin Microbiol Infect Dis. 2016;35(2):251\u20139.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"3","key":"540_CR72","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s40121-016-0122-1","volume":"5","author":"C Feher","year":"2016","unstructured":"Feher C, Mensa J. A comparison of current guidelines of five international societies on Clostridium difficile infection management. Infect Dis Ther. 2016;5(3):207\u201330.","journal-title":"Infect Dis Ther."},{"issue":"2","key":"540_CR73","doi-asserted-by":"crossref","first-page":"118","DOI":"10.2471\/BLT.14.138206","volume":"93","author":"E Marseille","year":"2015","unstructured":"Marseille E, Larson B, Kazi DS, Kahn JG, Rosen S. Thresholds for the cost-effectiveness of interventions: alternative approaches. Bull World Health Organ. 2015;93(2):118\u201324.","journal-title":"Bull World Health Organ"}],"container-title":["PharmacoEconomics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40273-017-0540-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0540-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40273-017-0540-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T15:47:56Z","timestamp":1750866476000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40273-017-0540-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":73,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["540"],"URL":"https:\/\/doi.org\/10.1007\/s40273-017-0540-2","relation":{},"ISSN":["1170-7690","1179-2027"],"issn-type":[{"value":"1170-7690","type":"print"},{"value":"1179-2027","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]}}}